StockData
Silence Therapeutics plc logo

Silence Therapeutics plc (SLN) stock

SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$19.82+0.02 (+0.10%)

Close on Nov 18, 2026Market cap $936.43MP/E –Yield –

Silence Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Silence Therapeutics's revenue for the twelve months ending Sep 30, 2026 was $456.00K, down 98.2% year over year. For fiscal 2025 it was $559.00K, down 98.7% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$559.00K-98.7%
FY2024Dec 31, 2024$43.26M+36.7%
FY2023Dec 31, 2023$31.64M+46.1%
FY2022Dec 31, 2022$21.66M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$0-100.0%
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$422.00K+197.2%
Q4 FY2025Dec 31, 2025$34.00K-99.9%
Q3 FY2025Sep 30, 2025$159.00K-89.4%
Q2 FY2025Jun 30, 2025$224.00K-70.4%
Q1 FY2025Mar 31, 2025$142.00K-99.1%
Q4 FY2024Dec 31, 2024$25.31M–
Q3 FY2024Sep 30, 2024$1.50M–
Q2 FY2024Jun 30, 2024$756.00K–
Q1 FY2024Mar 31, 2024$15.70M–

More Silence Therapeutics figures

See a number that looks wrong?